Method and combination for the suppression of COVID-19 virus
US12370236B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 20, 2022 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Oct 20, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a method for treating a SARS-CoV2 3CLpro-related disease in a subject in need thereof by blocking dimerization of 3C-like main protease (3CLpro) of the SARS-CoV2, including administering to the subject a first agent which binds to a first binding site of a SARS-CoV2 3CLpro complex and a second agent which binds to a second binding site of the SARS-CoV2 3CLpro complex, wherein the first binding site and the second binding site are functionally different sites in the three-dimensional structure of the SARS-CoV2 3CLpro complex. Also provided is a pharmaceutical combination including the first agent and the second agent for suppressing SARS-CoV2, thereby alleviating COVID-19.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.